More Argent Biopharma Ltd news
Argent Biopharma LtdASX: RGT

Long COVID Study Results for ArtemiC Support

Jul 14, 2022 at 7:50 AM EDT · Issued by Argent Biopharma Ltd

Filed with ASX · Jul 14, 2022 at 7:50 AM EDT

On 6ix: 6ix.com/news/long-covid-study-results-for-artemic-support

Argent Biopharma Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Argent Biopharma Ltd on 6ix

Story so far

  • ArtemiC Long COVID Syndrome Clinical Study CommencedDec 21, 2021
  • Completion of phase ii clinical trial on covid-19 patientsNov 5, 2020
  • Update on artemic phase ii trial on covid-19 patientsSep 28, 2020

Earlier from Argent Biopharma

  • Approvals received for South African CimetrA Clinical TrialJul 8, 2022
  • CimetrA anti-inflammatory pre-clinical study resultsJun 27, 2022
  • Glioblastoma pre-clinical trial resultsJun 16, 2022
  • Cognicann Clinical Trial ResultsJun 6, 2022
  • Response to ASX Aware QueryMay 17, 2022

Later from Argent Biopharma

  • June Quarter Activities and Cash Flow ReportJul 24, 2022
  • Amended June Quarterly Reports (amended App. 4C)Jul 24, 2022
  • Strategic Acquisition of 40% interest in ZAM Software LtdJul 28, 2022
  • US$10M Financing Agreement signed with US Financier/InvestorJul 29, 2022
  • US$1.2M Tranche 1 Funding Recevied from MercerAug 3, 2022
All Argent Biopharma news releases↗

Follow Argent Biopharma into a list and get an email when it puts out news.

Follow Argent Biopharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer